Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model
Context: The cardiotoxic effect of selective cyclo-oxygenase-2 inhibitors is well known. While rofecoxib and valdecoxib have been withdrawn, celecoxib remains on the market. Folic acid, a naturally occurring vitamin, has been shown to reduce myocardial ischemia and post-reperfusion injury in rats. O...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-01-01
|
| Series: | Pharmaceutical Biology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/13880209.2017.1299768 |
| _version_ | 1818248986606174208 |
|---|---|
| author | Shafique Ahmad Bibhu Prasad Panda Kanchan Kohli Mohammad Fahim Kiran Dubey |
| author_facet | Shafique Ahmad Bibhu Prasad Panda Kanchan Kohli Mohammad Fahim Kiran Dubey |
| author_sort | Shafique Ahmad |
| collection | DOAJ |
| description | Context: The cardiotoxic effect of selective cyclo-oxygenase-2 inhibitors is well known. While rofecoxib and valdecoxib have been withdrawn, celecoxib remains on the market. Folic acid, a naturally occurring vitamin, has been shown to reduce myocardial ischemia and post-reperfusion injury in rats. Objective: This study examined the cardiac effects of celecoxib and folic acid on doxorubicin-induced cardiomyopathy in rats. Materials and methods: Cardiomyopathy was induced in male Wistar rats with six intraperitoneal injections of 2.5 mg/kg doxorubicin over a period of two weeks. The effect of 28 days of celecoxib (100 mg/kg/day) and its combination with folic acid (10 mg/kg/day) was studied on doxorubicin-induced cardiomyopathy according to serum lactate dehydrogenase (LDH), creatine kinase (CK-MB), troponin-T (Tn-T), tumor necrosis factor alpha (TNF-α), cardiac thiobarbituric acid reactive substance (TBARS), and glutathione (GSH) levels as well as systolic blood pressure (SBP), heart rate (HR) and ultrastructural studies. Results: Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0.001) and TBARS (p < 0.01) levels and a significant decrease in the GSH (p < 0.05) level when used alone or administered with doxorubicin. However, the combination of folic acid with celecoxib caused a significant reversal of these parameters and reduced the cardiotoxicity of celecoxib that was aggravated by doxorubicin. The ultrastructural study also revealed myocardial protection with this combination. Discussion and conclusion: Folic acid protects against the cardiotoxic effects of celecoxib, which are aggravated in the presence of doxorubicin. Folic acid may act as a useful adjunct in patients who are taking celecoxib. |
| first_indexed | 2024-12-12T15:29:19Z |
| format | Article |
| id | doaj.art-982522b9fa70422aae00355650c84845 |
| institution | Directory Open Access Journal |
| issn | 1388-0209 1744-5116 |
| language | English |
| last_indexed | 2024-12-12T15:29:19Z |
| publishDate | 2017-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Pharmaceutical Biology |
| spelling | doaj.art-982522b9fa70422aae00355650c848452022-12-22T00:20:08ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162017-01-015511295130310.1080/13880209.2017.12997681299768Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat modelShafique Ahmad0Bibhu Prasad Panda1Kanchan Kohli2Mohammad Fahim3Kiran Dubey4Jamia HamdardJamia HamdardJamia HamdardHamdard Institute of Medical Sciences and Research, Jamia HamdardJamia HamdardContext: The cardiotoxic effect of selective cyclo-oxygenase-2 inhibitors is well known. While rofecoxib and valdecoxib have been withdrawn, celecoxib remains on the market. Folic acid, a naturally occurring vitamin, has been shown to reduce myocardial ischemia and post-reperfusion injury in rats. Objective: This study examined the cardiac effects of celecoxib and folic acid on doxorubicin-induced cardiomyopathy in rats. Materials and methods: Cardiomyopathy was induced in male Wistar rats with six intraperitoneal injections of 2.5 mg/kg doxorubicin over a period of two weeks. The effect of 28 days of celecoxib (100 mg/kg/day) and its combination with folic acid (10 mg/kg/day) was studied on doxorubicin-induced cardiomyopathy according to serum lactate dehydrogenase (LDH), creatine kinase (CK-MB), troponin-T (Tn-T), tumor necrosis factor alpha (TNF-α), cardiac thiobarbituric acid reactive substance (TBARS), and glutathione (GSH) levels as well as systolic blood pressure (SBP), heart rate (HR) and ultrastructural studies. Results: Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0.001) and TBARS (p < 0.01) levels and a significant decrease in the GSH (p < 0.05) level when used alone or administered with doxorubicin. However, the combination of folic acid with celecoxib caused a significant reversal of these parameters and reduced the cardiotoxicity of celecoxib that was aggravated by doxorubicin. The ultrastructural study also revealed myocardial protection with this combination. Discussion and conclusion: Folic acid protects against the cardiotoxic effects of celecoxib, which are aggravated in the presence of doxorubicin. Folic acid may act as a useful adjunct in patients who are taking celecoxib.http://dx.doi.org/10.1080/13880209.2017.1299768selective cox-2 inhibitorcardiovasculartn-ttnf-α |
| spellingShingle | Shafique Ahmad Bibhu Prasad Panda Kanchan Kohli Mohammad Fahim Kiran Dubey Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model Pharmaceutical Biology selective cox-2 inhibitor cardiovascular tn-t tnf-α |
| title | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model |
| title_full | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model |
| title_fullStr | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model |
| title_full_unstemmed | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model |
| title_short | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model |
| title_sort | folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model |
| topic | selective cox-2 inhibitor cardiovascular tn-t tnf-α |
| url | http://dx.doi.org/10.1080/13880209.2017.1299768 |
| work_keys_str_mv | AT shafiqueahmad folicacidamelioratescelecoxibcardiotoxicityinadoxorubicinheartfailureratmodel AT bibhuprasadpanda folicacidamelioratescelecoxibcardiotoxicityinadoxorubicinheartfailureratmodel AT kanchankohli folicacidamelioratescelecoxibcardiotoxicityinadoxorubicinheartfailureratmodel AT mohammadfahim folicacidamelioratescelecoxibcardiotoxicityinadoxorubicinheartfailureratmodel AT kirandubey folicacidamelioratescelecoxibcardiotoxicityinadoxorubicinheartfailureratmodel |